AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AMPLIA THERAPEUTICS LTD

0.150

-0.005-3.23%

Volume:1.05M

Turnover:162.95K

Market Cap:76.96M

PE:-7.44

High:0.160

Open:0.150

Low:0.145

Close:0.155

52wk High:0.425

52wk Low:0.049

Shares:513.07M

Float Shares:351.32M

Volume Ratio:0.74

T/O Rate:0.30%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.020

EPS(LYR):-0.021

ROE:-28.49%

ROA:-17.71%

PB:1.79

PE(LYR):-7.01

Loading ...

Overview Company News Filings

Amplia Therapeutics issues 240,385 shares on CMO option exercise under equity plan

Amplia Therapeutics Shares Up After Entering Agreement to Conduct Ovarian Cancer Clinical Study

MT Newswires Live

Amplia, ANZGOG launch PRROSE ovarian cancer trial of narmafotinib plus chemotherapy

Amplia, ANZGOG launch PRROSE ovarian cancer trial of narmafotinib with chemotherapy

Amplia presents mature ACCENT pancreatic cancer trial data at AACR meeting

Amplia Therapeutics Says No Toxicity Concerns Identified Regarding Narmafotinib Drug Candidate After Recruitment Halt in Clinical Trial

MT Newswires Live

Amplia MD says AMPLICITY halt driven by mFOLFIRINOX DLTs, not narmafotinib

Amplia Therapeutics Puts Trial Recruitment on Hold; Shares Dive 25%

MT Newswires Live

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Simply Wall St.

ASX Runners of the Week: Killi, Amplia, NuEnergy and 4D Medical

The West Australian

Amplia reports 7.8% complete response rate and 11.1-month median overall survival in ACCENT pancreatic cancer trial

Why this promising small-cap ASX stock could rise almost 80%

BRIEF-Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial

Amplia Therapeutics Ltd - Reports Updated Objective Response Rate of 35.9% in Accent Trial

THOMSON REUTERS

Amplia Therapeutics Reports 11.1-Month Median Survival, Five Complete Responses in Pancreatic Cancer Trial, Shares Surge 82%

MT Newswires Live

BRIEF-Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement

Amplia Therapeutics Ltd - Trading Halt Requested Pending Clinical Trial Results Announcement

THOMSON REUTERS

Amplia Therapeutics Says Preclinical Data Showed Drug Candidate Boosts kRAS Inhibitors in Cancer Treatment; Shares Fall 9%

MT Newswires Live

BRIEF-Amplia Therapeutics Announces Appointment Of Hamish George As CFO

Amplia Therapeutics Appoints CFO; Shares Fall 8%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","market":"AU","secType":"STK","nameCN":"AMPLIA THERAPEUTICS LTD","latestPrice":0.15,"timestamp":1778652720000,"preClose":0.155,"halted":0,"volume":1054509,"delay":0,"changeRate":-0.03225806451612906,"nameEN":"AMPLIA THERAPEUTICS LTD","floatShares":351321835,"shares":513071629,"eps":-0.020164,"marketStatus":"Not Yet Opened","change":-0.005,"latestTime":"05-13 16:12:00 AEST","open":0.15,"high":0.16,"low":0.145,"amount":162946,"amplitude":0.096774,"askPrice":0.16,"askSize":62000,"bidPrice":0.15,"bidSize":112941,"shortable":3,"etf":0,"ttmEps":-0.020164,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1778716800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.155,"openAndCloseTimeList":[[1778630400000,1778652000000]],"volumeRatio":0.741747,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ATX.AU","preClose":0.155,"auctionPrice":0.15,"auctionVolume":104148,"auction":3,"marketStatus":"盘后竞价","timestamp":1778652609418}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","floatShares":351321835,"roa":"-17.71%","roe":"-28.49%","lyrEps":-0.021392,"volumeRatio":0.741747,"shares":513071629,"dividePrice":0,"high":0.16,"amplitude":0.096774,"preClose":0.155,"low":0.145,"week52Low":0.049,"pbRate":"1.79","psRate":"15.37","week52High":0.425,"institutionHeld":0,"latestPrice":0.15,"committee":0.29119,"eps":-0.020164,"divideRate":0,"volume":1054509,"delay":0,"ttmEps":-0.020164,"open":0.15,"prevYearClose":0.15,"prevWeekClose":0.13,"prevMonthClose":0.15,"prevQuarterClose":0.235,"fiveDayClose":0.135,"twentyDayClose":0.165,"sixtyDayClose":0.12,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATX.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-04-18","symbol":"ATX.AU","defaultRemindTime":1713398400000,"type":"split","dateTimestamp":1713362400000,"forFactor":971896,"toFactor":1000000,"ratio":0.971896}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634603912","title":"Amplia Therapeutics issues 240,385 shares on CMO option exercise under equity plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2634603912","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634603912?lang=en_us&edition=fundamental","pubTime":"2026-05-12 14:53","pubTimestamp":1778568819,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics issued 240,385 fully paid ordinary shares from exercise of Zero Exercise Price Options under its Equity Incentive Plan.New shares will rank pari passu with existing ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Ltd. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLjRcY6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634524475","title":"Amplia Therapeutics Shares Up After Entering Agreement to Conduct Ovarian Cancer Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2634524475","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634524475?lang=en_us&edition=fundamental","pubTime":"2026-05-11 10:45","pubTimestamp":1778467518,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  shares were up nearly 2% in recent trading on Monday after it said in a statement on Friday that it entered into an agreement with the Australia New Zealand Gynaecological Oncology Group to conduct a clinical study investigating its drug candidate narmafotinib in ovarian cancer.The study will evaluate the safety of narmafotinib in combination with standard-of-care chemotherapy .It is expected to enroll around 15 to 20 patients with high-grade serous ovarian cancer, who demonstrate poor response to up-front standard-of-care platinum-based chemotherapy before planned interval debulking surgery.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK4007","BK4539","ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634397448","title":"Amplia, ANZGOG launch PRROSE ovarian cancer trial of narmafotinib plus chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2634397448","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634397448?lang=en_us&edition=fundamental","pubTime":"2026-05-10 08:01","pubTimestamp":1778371268,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics entered an agreement with ANZGOG to run an investigator-initiated PRROSE clinical trial in ovarian cancer, testing narmafotinib with standard chemotherapy.Trial will enroll about 15-20 patients with high-grade serous ovarian cancer who did not respond to platinum-based chemotherapy before planned surgery.Study will assess safety, then explore whether adding narmafotinib can improve post-surgical outcomes by increasing likelihood of successful tumor removal.No trial results have been presented; biomarker work is planned during study to support future readouts on how drug is working.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Ltd. published the original content used to generate this news brief ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nNDL2GDK3F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633910641","title":"Amplia, ANZGOG launch PRROSE ovarian cancer trial of narmafotinib with chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2633910641","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633910641?lang=en_us&edition=fundamental","pubTime":"2026-05-08 07:57","pubTimestamp":1778198254,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics entered agreement with Australia New Zealand Gynaecological Oncology Group to run investigator-initiated PRROSE study in ovarian cancer, testing lead drug narmafotinib with standard chemotherapy.Results have not been presented; trial will generate future safety readout, with exploratory assessment of whether combination can improve surgery eligibility and post-surgical outcomes in high-grade serous ovarian cancer patients who did not respond to initial platinum-based treatment.Planned enrollment about 15-20 patients across ANZGOG network, positioning program to broaden narmafotinib development beyond pancreatic cancer into fibrotic ovarian tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Lt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL33GSm3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629204906","title":"Amplia presents mature ACCENT pancreatic cancer trial data at AACR meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629204906","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629204906?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:45","pubTimestamp":1776861951,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics is presenting mature results from its ACCENT trial in metastatic pancreatic cancer at AACR annual meeting today.Data showed narmafotinib combined with standard chemotherapy delivered stronger anti-tumor activity than chemotherapy alone, without adding a meaningful tolerability burden.Study also indicated longer survival outcomes versus chemotherapy alone, supporting plans to advance narmafotinib into additional clinical studies including a pivotal trial.Amplia signaled future trials will shift to daily narmafotinib dosing, aiming to build on the responses seen with an intermittent schedule.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL1Bbk8f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4112","LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014021.USD","BK7067","BK4588","IE00BGHQF748.EUR","NDAQ","BK4585","IE00BN0W2V16.EUR","SG9999014013.SGD","ATX.AU","SG9999014039.USD","LU0314104364.USD","IE00BKPKM429.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625990188","title":"Amplia Therapeutics Says No Toxicity Concerns Identified Regarding Narmafotinib Drug Candidate After Recruitment Halt in Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2625990188","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625990188?lang=en_us&edition=fundamental","pubTime":"2026-04-08 14:26","pubTimestamp":1775629615,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  said no toxicity concerns were identified regarding its drug candidate narmafotinib, and its Chief Executive Christopher Burns said the results do not impact the firm's plans to explore combinations of narmafotinib, according to a Wednesday Australian bourse filing.It halted further recruitment in the Amplicity clinical trial following three dose-limiting toxicities related to the chemotherapy regimen modified Folfirinox.The remaining five patients will remain on study and continue to receive the combination with continued safety monitoring.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4007","BK4139","LENZ","ATX.AU","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625994193","title":"Amplia MD says AMPLICITY halt driven by mFOLFIRINOX DLTs, not narmafotinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2625994193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625994193?lang=en_us&edition=fundamental","pubTime":"2026-04-08 12:46","pubTimestamp":1775623605,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics issued a managing director video response on April 8, 2026, addressing shareholder questions on its decision to halt further recruitment in AMPLICITY, a pancreatic cancer trial combining narmafotinib with mFOLFIRINOX.Recruitment was paused following three dose-limiting toxicities tied to mFOLFIRINOX.Management reported no toxicity concerns identified for narmafotinib.Patients already enrolled will remain in the study and continue treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Ltd. published the original content used to generate this news brief on April 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL4xd4Mv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625697988","title":"Amplia Therapeutics Puts Trial Recruitment on Hold; Shares Dive 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625697988","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625697988?lang=en_us&edition=fundamental","pubTime":"2026-04-07 08:22","pubTimestamp":1775521335,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  stopped further recruitment in the Amplicity clinical trial following three dose-limiting toxicities, according to a Tuesday filing with the Australian bourse.The trial is investigating the company's lead drug narmafotinib in combination with the chemotherapy regimen modified Folfirinox in advanced pancreatic cancer, the filing said.Among the eight patients, three events of protocol-defined dose-limiting toxicities have been observed relating to the chemotherapy regimen.The remaining five patients will remain on study and continue to receive the combination with continued safety monitoring, per the filing.The company's shares tumbled 25% in recent Tuesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK4007","BK4539","ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624554137","title":"Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2624554137","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624554137?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:39","pubTimestamp":1774989598,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. By way of example, Amplia...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-atx/amplia-therapeutics-shares/news/companies-like-amplia-therapeutics-asxatx-are-in-a-position-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-atx/amplia-therapeutics-shares/news/companies-like-amplia-therapeutics-asxatx-are-in-a-position-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622810960","title":"ASX Runners of the Week: Killi, Amplia, NuEnergy and 4D Medical","url":"https://stock-news.laohu8.com/highlight/detail?id=2622810960","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622810960?lang=en_us&edition=fundamental","pubTime":"2026-03-27 06:12","pubTimestamp":1774563129,"startTime":"0","endTime":"0","summary":"The Bulls N’ Bears ASX Runner of the Week is… Killi Resources, after a boardroom makeover, lured in ex-Fortescue boss Nev Power for a bold tilt at its Mt Rawdon West, QLD gold-copper play. ","market":"us","thumbnail":"https://images.thewest.com.au/publication/C-22058751/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22058751/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-killi-amplia-nuenergy-and-4d-medical-c-22058751","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-killi-amplia-nuenergy-and-4d-medical-c-22058751","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["BK4182","ATX.AU","BK4588","BK7067","BK7142","KLI.AU","PSC.AU","VDE","4DX.AU","BK7095","BK4585","BK4535","XME","PSC","BK7094","NGY.AU","BK4213","CEI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621098994","title":"Amplia reports 7.8% complete response rate and 11.1-month median overall survival in ACCENT pancreatic cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621098994","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621098994?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:50","pubTimestamp":1774360258,"startTime":"0","endTime":"0","summary":"Central review identified four additional confirmed complete responses, bringing the total to five complete responses  among 64 patients receiving 400 mg narmafotinib.The updated objective response rate was 35.9%  for patients treated at the 400 mg dose.Overall survival analysis with a mid-March data cutoff showed a median overall survival of 11.1 months.Amplia said the ACCENT trial data will be presented at the American Association of Cancer Research annual meeting in April 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL3n835f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","ATX.AU","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","BK4588","LU2095319765.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","BK7067","NDAQ","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621087206","title":"Why this promising small-cap ASX stock could rise almost 80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087206","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087206?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:42","pubTimestamp":1774302152,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics Ltd  shares certainly had a day to remember on Monday. When many ASX shares were tumbling with the market, this small-cap stock doubled in value to 23.5 cents. The catalyst for this was the release of updated data from the single-arm Phase 1b/2 ACCENT trial evaluating narmafotinib plus chemotherapy in 64 metastatic pancreatic cancer patients. Image source: Getty Images Is it too late to buy this small-cap ASX stock?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/24/why-this-promising-small-cap-asx-stock-could-rise-almost-80/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/24/why-this-promising-small-cap-asx-stock-could-rise-almost-80/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621705085","title":"BRIEF-Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621705085","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621705085?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:49","pubTimestamp":1774270191,"startTime":"0","endTime":"0","summary":"BRIEF-Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer TrialAmplia Therapeutics Ltd ATX.AX:AMPLIA THERAPEUTICS REPORTS FOUR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUAC0BZZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621730705","title":"Amplia Therapeutics Ltd - Reports Updated Objective Response Rate of 35.9% in Accent Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621730705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621730705?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:45","pubTimestamp":1774269900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUAC0BZZP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621255987","title":"Amplia Therapeutics Reports 11.1-Month Median Survival, Five Complete Responses in Pancreatic Cancer Trial, Shares Surge 82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621255987","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621255987?lang=en_us&edition=fundamental","pubTime":"2026-03-23 10:43","pubTimestamp":1774233784,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  said mature data from its ongoing ACCENT clinical trial in advanced pancreatic cancer showed a median overall survival of 11.1 months and five complete responses to date, with its lead drug candidate narmafotinib combined with chemotherapy, according to a Monday Australian bourse filing.The company said five patients have achieved a complete response in the Phase 1b/2a trial, resulting in a complete response rate of 7.8%.The median overall survival of 11.1 months represents a two-month improvement compared to chemotherapy alone, with no additional toxicity burden, the filing added.Narmafotinib is the company's inhibitor of the protein FAK, which is overexpressed in pancreatic cancer and is gaining \"increasing attention\" as a drug target in solid tumors, the filing added.Amplia said it has been chosen to present trial data at the annual meeting of the American Association of Cancer Research  in San Diego in April.The company's shares surged past 82% to reach their h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LENZ","BK7067","BK4539","ATX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620296224","title":"BRIEF-Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620296224","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620296224?lang=en_us&edition=fundamental","pubTime":"2026-03-19 07:58","pubTimestamp":1773878289,"startTime":"0","endTime":"0","summary":"BRIEF-Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results AnnouncementMarch 19 (Reuters) - Amplia Therapeutics Ltd ATX.AX:TRADING HALT REQUESTED PENDING CLINICAL TRIAL RESULTS ANNOUNCEMENTFurther company coverage: ATX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4061A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620129624","title":"Amplia Therapeutics Ltd - Trading Halt Requested Pending Clinical Trial Results Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620129624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620129624?lang=en_us&edition=fundamental","pubTime":"2026-03-19 07:57","pubTimestamp":1773878260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4061A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618619241","title":"Amplia Therapeutics Says Preclinical Data Showed Drug Candidate Boosts kRAS Inhibitors in Cancer Treatment; Shares Fall 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618619241","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618619241?lang=en_us&edition=fundamental","pubTime":"2026-03-09 12:06","pubTimestamp":1773029208,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics (ASX:ATX) said preclinical data showed that its focal adhesion kinase inhibitor narmafotinib boosts the activity of a class of drugs called kRAS inhibitors in various models of can","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LENZ","BK4539","BK4139","ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614773118","title":"BRIEF-Amplia Therapeutics Announces Appointment Of Hamish George As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2614773118","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614773118?lang=en_us&edition=fundamental","pubTime":"2026-02-25 10:26","pubTimestamp":1771986389,"startTime":"0","endTime":"0","summary":"BRIEF-Amplia Therapeutics Announces Appointment Of Hamish George As CFOFeb 25 (Reuters) - Amplia Therapeutics Ltd ATX.AX:APPOINTMENT OF HAMISH GEORGE AS CHIEF FINANCIAL OFFICERFurther company coverage: ATX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUEBN3MBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614727304","title":"Amplia Therapeutics Appoints CFO; Shares Fall 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614727304","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614727304?lang=en_us&edition=fundamental","pubTime":"2026-02-25 08:57","pubTimestamp":1771981024,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics (ASX:ATX) has appointed Hamish George as chief financial officer, succeeding Tim Luscombe, effective Wednesday, according to a same-day filing with the Australian bourse.The company's shares fell around 8% in recent Wednesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ATX.AU","LENZ","BK4007","BK7067","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}